The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

We recently published a list of the 10 Worst Performing Stocks in S&P 500 in 2024. In this article, we are going to take a ...

Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. Vandana Singh Benzinga Bulls And ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vir Biotechnology (VIR – Research Report) and Moderna (MRNA ...

The most recent trading session ended with Moderna (MRNA) standing at $57.73 ... estimates have a direct correlation with impending stock price performance. To take advantage of this, we've ...

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...

If an investor was to purchase shares of MRNA stock at the current price level of $57.91/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...